| Metric | Value | Detail |
|---|---|---|
| Revenue | $61.2B | +8.6% YoY |
| Net income | $4.2B | 6.9% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 24.6% | Operating income / revenue |
| Return on equity | n/a | Net income / equity |
| Return on assets | 3% | Net income / assets |
| Revenue growth (YoY) | +8.6% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +1.8% | Compound annual |
| Diluted EPS | $2.37 | FY2025 |
| Debt-to-equity | n/a | Long-term debt / equity |
| Current ratio | 0.67 | Current assets / liabilities |
| Cash & equivalents | $5.2B | Balance sheet |
| Total assets | $134.0B | FY2025 year-end |
| Shareholders’ equity | −$3.2B | FY2025 year-end |
| Share price | $248.08 | Delayed · 2026-07-10 |
| Market cap | $438.3B | Price × shares outstanding |
| P/E ratio | 103.5 | Market cap / net income |
| P/S ratio | 7.2 | Market cap / revenue |
| Dividend yield | 2.68% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
AbbVie Inc. (ABBV) stock fundamentals
AbbVie Inc. (ABBV) reported $61.2B in revenue and $4.2B in net income in fiscal 2025, a 6.9% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $438.3B at a delayed share price. It scores 28/100 on WealthyBud's Investor Score, ranking #93 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$61.2B
▲ +8.6% YoY
Net income
$4.2B
6.9% net margin
Market cap
$438.3B
Price $248.08 · delayed
P/E ratio
103.5
Price / earnings
Return on equity
n/a
Net income / equity
Investor Score
28/100
#93 of 100 covered
AbbVie Inc. fundamentals at a glance
The table summarizes AbbVie Inc.'s key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is AbbVie Inc.?
AbbVie Inc. runs a 6.9% net margin and n/a gross margin in fiscal 2025, turning $61.2B of revenue into $4.2B of profit. Return on equity is n/a and return on assets 3%.
Is AbbVie Inc. growing?
AbbVie Inc.'s revenue changed +8.6% in fiscal 2025 and compounded at +1.8% a year over three years, reaching $61.2B. Diluted earnings per share were $2.37 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $56.2B | n/a |
| 2022 | $58.1B | +3.3% |
| 2023 | $54.3B | -6.4% |
| 2024 | $56.3B | +3.7% |
| 2025 | $61.2B | +8.6% |
How is AbbVie Inc. valued?
AbbVie Inc. carries a market capitalization of $438.3B at a delayed share price of $248.08, trading at a 103.5 price-to-earnings ratio and 7.2 price-to-sales with a 2.68% dividend yield. Its Value subscore is 36/100 across the covered universe.
How financially healthy is AbbVie Inc.?
AbbVie Inc. ended fiscal 2025 with $5.2B in cash, a debt-to-equity ratio of n/a and a current ratio of 0.67. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is AbbVie Inc.'s Investor Score?
AbbVie Inc. scores 28/100 on WealthyBud's Investor Score, #93 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
28/100
#93 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
AbbVie Inc. (ABBV) stock FAQ
How much revenue does AbbVie Inc. make?
AbbVie Inc. (ABBV) reported $61.2B in revenue in fiscal 2025, +8.6% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +1.8% a year.
Is AbbVie Inc. profitable?
Yes. AbbVie Inc. earned $4.2B in net income in fiscal 2025, a 6.9% net margin. Its return on equity was n/a and return on assets 3%, based on figures from its latest 10-K.
How fast is AbbVie Inc. growing?
AbbVie Inc.'s revenue changed +8.6% year over year in fiscal 2025 and compounded at +1.8% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 43/100 versus the covered universe.
What is AbbVie Inc.'s market cap and P/E ratio?
AbbVie Inc. has a market capitalization of $438.3B at a delayed share price of $248.08, trading at a price-to-earnings ratio of 103.5 and price-to-sales of 7.2. Its dividend yield is 2.68%. Prices are delayed and illustrative.
What is AbbVie Inc.'s WealthyBud Investor Score?
AbbVie Inc. scores 28/100, ranking #93 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (43), profitability (34), returns on capital (12), balance-sheet strength (5) and value (36). It is a research opinion, not investment advice.
Where does this AbbVie Inc. financial data come from?
Fundamentals come from AbbVie Inc.'s annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from AbbVie Inc.’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.